Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded down 4% on Wednesday . The stock traded as low as $52.01 and last traded at $52.24, with a volume of 562,668 shares changing hands. The stock had previously closed at $54.40.

Several analysts have recently weighed in on the stock. Credit Suisse Group AG restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday. Wedbush restated an “outperform” rating and set a $92.00 price objective (down previously from $99.00) on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Jefferies Group restated a “buy” rating and set a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Finally, Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, May 10th. Three investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $99.32.

The firm’s 50 day moving average price is $59.06 and its 200 day moving average price is $65.72. The company’s market cap is $1.98 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.29) by $0.06. During the same period in the previous year, the company posted ($0.63) EPS. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post ($5.84) earnings per share for the current fiscal year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the completion of the transaction, the chief executive officer now owns 526,704 shares in the company, valued at $31,575,904.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sunil Agarwal sold 650 shares of the company’s stock in a transaction on Monday, June 20th. The stock was sold at an average price of $54.16, for a total transaction of $35,204.00. The disclosure for this sale can be found here.

Other institutional investors recently modified their holdings of the company. Dimensional Fund Advisors LP raised its position in shares of Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 5,139 shares in the last quarter. Jennison Associates LLC raised its position in shares of Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock worth $84,739,000 after buying an additional 109,724 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $1,010,000. Wells Fargo & Company MN raised its position in shares of Ultragenyx Pharmaceutical by 14.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,774,736 shares of the biopharmaceutical company’s stock worth $199,090,000 after buying an additional 219,746 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 33,497 shares of the biopharmaceutical company’s stock worth $3,758,000 after buying an additional 497 shares in the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.